200,000+ products from a single source!
sales@angenechem.com
461432-26-8 | (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol
CAS No: 461432-26-8 Catalog No: AG0039GJ MDL No:MFCD13182359
Product Description
Catalog Number:
AG0039GJ
Chemical Name:
(1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol
CAS Number:
461432-26-8
Molecular Formula:
C21H25ClO6
Molecular Weight:
408.8726
MDL Number:
MFCD13182359
IUPAC Name:
(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
InChI:
InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
InChI Key:
JVHXJTBJCFBINQ-ADAARDCZSA-N
SMILES:
CCOc1ccc(cc1)Cc1cc(ccc1Cl)[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O
UNII:
1ULL0QJ8UC
Properties
Complexity:
472
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
5
Defined Bond Stereocenter Count:
0
Exact Mass:
408.134g/mol
Formal Charge:
0
Heavy Atom Count:
28
Hydrogen Bond Acceptor Count:
6
Hydrogen Bond Donor Count:
4
Isotope Atom Count:
0
Molecular Weight:
408.875g/mol
Monoisotopic Mass:
408.134g/mol
Rotatable Bond Count:
6
Topological Polar Surface Area:
99.4A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.3
Literature
| Title | Journal |
|---|---|
| SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. | Toxicology and applied pharmacology 20171015 |
| Pharmacological aspects of the safety of gliflozins. | Pharmacological research 20170401 |
| Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. | Clinical pharmacokinetics 20150701 |
| Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. | Clinical pharmacokinetics 20140101 |
| Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. | Diabetes, obesity & metabolism 20121101 |
| Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. | Diabetes, obesity & metabolism 20121001 |
| Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. | Journal of medicinal chemistry 20120913 |
| Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors. | European journal of medicinal chemistry 20120901 |
| Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? | Diabetes 20120901 |
| Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. | Obesity (Silver Spring, Md.) 20120801 |
| Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. | Diabetes care 20120701 |
| C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. | Bioorganic & medicinal chemistry 20120701 |
| Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. | Postgraduate medicine 20120701 |
| A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. | Annals of medicine 20120601 |
| [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes]. | Yao xue xue bao = Acta pharmaceutica Sinica 20120601 |
| [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors]. | Orvosi hetilap 20120506 |
| Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. | International journal of clinical practice 20120501 |
| Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents. | Expert opinion on therapeutic patents 20120501 |
| SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. | Journal of clinical pharmacology 20120401 |
| Dapagliflozin for the treatment of type 2 diabetes. | The Annals of pharmacotherapy 20120401 |
| Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. | Annals of internal medicine 20120320 |
| Still uncertain about sodium-glucose cotransporter inhibitors despite 2 centuries of study. | Annals of internal medicine 20120320 |
| Summaries for patients: Dapagliflozin treatment in patients with inadequately controlled type 2 diabetes despite the use of insulin. | Annals of internal medicine 20120320 |
| Stereoselective C-glycosylation reactions with arylzinc reagents. | Organic letters 20120316 |
| Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. | The Journal of clinical endocrinology and metabolism 20120301 |
| FDA rejects novel diabetes drug over safety fears. | Lancet (London, England) 20120211 |
| Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. | Advances in therapy 20120201 |
| Structural selectivity of human SGLT inhibitors. | American journal of physiology. Cell physiology 20120115 |
| Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. | American journal of physiology. Regulatory, integrative and comparative physiology 20120101 |
| Facile synthesis of 1,2,3-triazole analogs of SGLT2 inhibitors by 'click chemistry'. | Bioorganic & medicinal chemistry letters 20120101 |
| Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. | PloS one 20120101 |
| Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. | Pharmacotherapy 20120101 |
| Red carpeting the newer antidiabetics. | Journal of pharmacology & pharmacotherapeutics 20120101 |
| The management of type 2 diabetic patients with hypoglycaemic agents. | ISRN endocrinology 20120101 |
| Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. | Core evidence 20120101 |
| Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. | Diabetes, metabolic syndrome and obesity : targets and therapy 20120101 |
| Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20120101 |
| Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. | BMJ open 20120101 |
| Drugs in traffic: the road to approval. | Nature medicine 20111206 |
| Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology. | The AAPS journal 20111201 |
| The role of visfatin in diabetic nephropathy. | Chonnam medical journal 20111201 |
| Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. | Clinical therapeutics 20111101 |
| Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus. | Expert review of clinical pharmacology 20111101 |
| Dapagliflozin--redefining treatment of T2DM? | Nature reviews. Endocrinology 20111011 |
| Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. | Diabetes, obesity & metabolism 20111001 |
| Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents. | Bioorganic & medicinal chemistry 20111001 |
| Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents. | Bioorganic & medicinal chemistry 20110915 |
| Kidney in diabetes: from organ damage target to therapeutic target. | Current drug metabolism 20110901 |
| Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. | Diabetes care 20110901 |
| Challenges for the treatment of diabetes mellitus. | Recent patents on endocrine, metabolic & immune drug discovery 20110901 |
| Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901 |
| Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901 |
| [Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes]. | Revue medicale suisse 20110831 |
| Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. | Diabetes, obesity & metabolism 20110801 |
| Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors. | European journal of medicinal chemistry 20110701 |
| A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition. | Postgraduate medicine 20110701 |
| Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors. | Bioorganic & medicinal chemistry letters 20110615 |
| Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors. | Bioorganic & medicinal chemistry letters 20110615 |
| New diabetes drugs go beyond insulin to flush out excess sugar. | Nature medicine 20110601 |
| Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. | Journal of medicinal chemistry 20110428 |
| Discovery of non-glucoside SGLT2 inhibitors. | Bioorganic & medicinal chemistry letters 20110415 |
| Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. | Diabetes, obesity & metabolism 20110401 |
| Learning from glycosuria. | Diabetes 20110301 |
| SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. | Diabetes 20110301 |
| Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. | Kidney international. Supplement 20110301 |
| A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors. | Discovery medicine 20110301 |
| Type 2 diabetes: uses of thiazolidinediones and insulin. | Diabetes care 20110201 |
| Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2. | Bioorganic & medicinal chemistry letters 20110115 |
| Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. | Journal of medicinal chemistry 20110113 |
| Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. | Diabetes, obesity & metabolism 20110101 |
| Development of sodium-dependent glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics. | Current topics in medicinal chemistry 20110101 |
| Diabetic nephropathy - Epidemiology in Asia and the current state of treatment. | Indian journal of nephrology 20110101 |
| Management of diabetes across the course of disease: minimizing obesity-associated complications. | Diabetes, metabolic syndrome and obesity : targets and therapy 20110101 |
| SGLT-2 inhibitors in development for type 2 diabetes treatment. | The review of diabetic studies : RDS 20110101 |
| Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors. | Bioorganic & medicinal chemistry letters 20101201 |
| Dapagliflozin: more than just another oral glucose-lowering agent? | Expert opinion on investigational drugs 20101201 |
| Validated LC-MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma. | Bioanalysis 20101201 |
| [Renal SGLT2 inhibitors: a new type of oral anti-hyperglycemia drugs]. | Sheng li ke xue jin zhan [Progress in physiology] 20101201 |
| Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201 |
| Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201 |
| A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors. | North American journal of medical sciences 20101201 |
| The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. | Diabetes, obesity & metabolism 20101101 |
| Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. | Diabetes care 20101001 |
| Diabetes: Dapagliflozin: an insulin-independent, therapeutic option for type 2 diabetes mellitus. | Nature reviews. Endocrinology 20101001 |
| Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. | Current opinion in nephrology and hypertension 20100901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100901 |
| Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors. | Bioorganic & medicinal chemistry 20100815 |
| (5-Bromo-2-methyl-phen-yl)(4-eth-oxy-phen-yl)methanone. | Acta crystallographica. Section E, Structure reports online 20100801 |
| Dapagliflozin, an SGLT2 inhibitor, for diabetes. | Lancet (London, England) 20100626 |
| Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. | Lancet (London, England) 20100626 |
| ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. | Bioorganic & medicinal chemistry 20100615 |
| Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners. | Bioorganic & medicinal chemistry letters 20100601 |
| Neuropathy, retinopathy, and glucose-lowering treatments. | Diabetes care 20100601 |
| Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. | Diabetes, obesity & metabolism 20100601 |
| Dapagliflozin: BMS 512148; BMS-512148. | Drugs in R&D 20100501 |
| (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. | Journal of medicinal chemistry 20100422 |
| Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners. | Bioorganic & medicinal chemistry 20100315 |
| Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. | Drugs 20100305 |
| In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. | Drug metabolism and disposition: the biological fate of chemicals 20100301 |
| C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization. | Bioorganic & medicinal chemistry letters 20100301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100101 |
| [Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20100101 |
| Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. | Bioorganic & medicinal chemistry letters 20091215 |
| Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. | IDrugs : the investigational drugs journal 20091201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20091201 |
| (5-Bromo-2-chloro-phen-yl)(4-ethoxy-phen-yl)methanone. | Acta crystallographica. Section E, Structure reports online 20091201 |
| Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. | Journal of medicinal chemistry 20091022 |
| O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. | Bioorganic & medicinal chemistry letters 20091001 |
| Dapagliflozin: where does it fit in the treatment of type 2 diabetes? | Expert opinion on pharmacotherapy 20091001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20091001 |
| A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. | Diabetes care 20090901 |
| Dapagliflozin for the treatment of type 2 diabetes. | The Annals of pharmacotherapy 20090701 |
| Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. | Kidney international 20090601 |
| Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. | Clinical pharmacology and therapeutics 20090501 |
| Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. | Clinical pharmacology and therapeutics 20090501 |
| Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. | Journal of medicinal chemistry 20090409 |
| Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. | Diabetes care 20090401 |
| Dapagliflozin: an emerging treatment option in type 2 diabetes. | Expert opinion on investigational drugs 20090301 |
| Diabetes treatment. | Diabetes care 20090301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090301 |
| Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. | Diabetes, obesity & metabolism 20090201 |
| Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080901 |
| Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. | International journal of clinical practice 20080801 |
| Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. | Diabetes 20080601 |
| Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. | Journal of medicinal chemistry 20080313 |
| Molecule of the month. Dapagliflozin. | Drug news & perspectives 20071201 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.